Enanta Pharmaceuticals (ENTA) Stock Forecast, Price Target & Predictions
ENTA Stock Forecast
Enanta Pharmaceuticals stock forecast is as follows: an average price target of $65.67 (represents a 945.70% upside from ENTA’s last price of $6.28) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ENTA Price Target
The average price target for Enanta Pharmaceuticals (ENTA) is $65.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $87.00 to $54.00. This represents a potential 945.70% upside from ENTA's last price of $6.28.
ENTA Analyst Ratings
According to 4 Wall Street analysts, Enanta Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ENTA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Enanta Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2022 | H.C. Wainwright | $56.00 | $41.96 | 33.46% | 791.72% | |
| Nov 22, 2022 | RBC Capital | $54.00 | $46.40 | 16.38% | 759.87% | |
| Jul 29, 2022 | Yasmeen Rahimi | Piper Sandler | $87.00 | $51.27 | 69.67% | 1285.35% |
The latest Enanta Pharmaceuticals stock forecast, released on Dec 09, 2022 by H.C. Wainwright company, set a price target of $56.00, which represents a 33.46% increase from the stock price at the time of the forecast ($41.96), and a 791.72% increase from ENTA last price ($6.28).
Enanta Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.28 | $6.28 | $6.28 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Enanta Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enanta Pharmaceuticals's last price of $6.28. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Feb 08, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 22, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jul 29, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 06, 2022 | Evercore ISI | Outperform | Upgrade |
Enanta Pharmaceuticals's last stock rating was published by JMP Securities on Oct 09, 2024. The company gave ENTA a "Market Outperform" rating, the same as its previous rate.
Enanta Pharmaceuticals Financial Forecast
Enanta Pharmaceuticals Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $18.00M | $18.93M | $18.89M | $17.80M | $23.59M | $20.32M | $19.48M | $18.72M | $27.65M | $23.57M | $21.62M | $20.13M | $31.74M | $23.63M | $18.65M | $27.62M | $52.57M | $51.31M | $44.37M | $39.63M | $44.05M | $8.96M | $13.00M |
| Avg Forecast | $15.44M | $16.49M | $16.57M | $18.00M | $17.93M | $17.44M | $16.09M | $21.95M | $17.49M | $18.19M | $19.04M | $23.55M | $23.13M | $20.65M | $20.67M | $27.37M | $26.34M | $21.86M | $24.38M | $27.73M | $25.55M | $26.32M | $30.05M | $58.07M | $55.94M | $46.98M | $40.88M | $38.27M | $12.16M | $14.44M |
| High Forecast | $16.10M | $17.19M | $16.71M | $19.89M | $17.96M | $17.44M | $16.09M | $22.75M | $33.07M | $18.97M | $19.86M | $24.56M | $23.13M | $20.65M | $20.67M | $27.37M | $26.34M | $21.86M | $24.38M | $27.73M | $25.55M | $26.32M | $30.05M | $58.07M | $55.94M | $46.98M | $40.88M | $45.93M | $14.59M | $17.33M |
| Low Forecast | $14.78M | $15.78M | $16.42M | $16.09M | $17.90M | $17.44M | $16.09M | $21.13M | $7.85M | $17.41M | $18.23M | $22.55M | $23.13M | $20.65M | $20.67M | $27.37M | $26.34M | $21.86M | $24.38M | $27.73M | $25.55M | $26.32M | $30.05M | $58.07M | $55.94M | $46.98M | $40.88M | $30.62M | $9.73M | $11.56M |
| # Analysts | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 11 | 10 |
| Surprise % | - | - | - | - | - | - | - | 0.82% | 1.08% | 1.04% | 0.93% | 1.00% | 0.88% | 0.94% | 0.91% | 1.01% | 0.90% | 0.99% | 0.83% | 1.14% | 0.92% | 0.71% | 0.92% | 0.91% | 0.92% | 0.94% | 0.97% | 1.15% | 0.74% | 0.90% |
Enanta Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.09M, with a low forecast of $16.09M, and a high forecast of $16.09M. ENTA's average Quarter revenue forecast represents a -10.61% decrease compared to the company's last Quarter revenue of $18.00M (Dec 23).
Enanta Pharmaceuticals EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 11 | 10 |
| EBITDA | - | - | - | - | - | - | - | $-29.95M | $-25.70M | $-36.71M | $-39.45M | $-30.01M | $-26.39M | $-31.82M | $-33.02M | $-29.37M | $-32.59M | $-32.59M | $-27.78M | $-10.75M | $-17.73M | $-20.49M | $-7.06M | $17.93M | $9.60M | $7.05M | $1.74M | $18.54M | $-8.42M | $351.00K |
| Avg Forecast | $-13.31M | $-14.21M | $-14.28M | $-15.52M | $-15.46M | $-15.04M | $-45.11M | $-18.92M | $-15.08M | $-15.68M | $-35.66M | $-22.30M | $-14.62M | $-13.06M | $-28.19M | $-17.30M | $-16.65M | $-13.82M | $-24.66M | $-17.53M | $-16.15M | $-16.64M | $-10.57M | $-36.71M | $-35.37M | $-29.70M | $7.06M | $15.74M | $-10.64M | $916.11K |
| High Forecast | $-12.74M | $-13.61M | $-14.15M | $-13.87M | $-15.43M | $-15.04M | $-36.08M | $-18.22M | $-6.76M | $-15.01M | $-28.53M | $-17.84M | $-14.62M | $-13.06M | $-22.55M | $-17.30M | $-16.65M | $-13.82M | $-19.73M | $-17.53M | $-16.15M | $-16.64M | $-8.45M | $-36.71M | $-35.37M | $-29.70M | $8.47M | $18.89M | $-8.51M | $1.10M |
| Low Forecast | $-13.88M | $-14.82M | $-14.41M | $-17.15M | $-15.49M | $-15.04M | $-54.13M | $-19.61M | $-28.51M | $-16.35M | $-42.79M | $-26.76M | $-14.62M | $-13.06M | $-33.82M | $-17.30M | $-16.65M | $-13.82M | $-29.59M | $-17.53M | $-16.15M | $-16.64M | $-12.68M | $-36.71M | $-35.37M | $-29.70M | $5.65M | $12.59M | $-12.76M | $732.89K |
| Surprise % | - | - | - | - | - | - | - | 1.58% | 1.70% | 2.34% | 1.11% | 1.35% | 1.81% | 2.44% | 1.17% | 1.70% | 1.96% | 2.36% | 1.13% | 0.61% | 1.10% | 1.23% | 0.67% | -0.49% | -0.27% | -0.24% | 0.25% | 1.18% | 0.79% | 0.38% |
4 analysts predict ENTA's average Quarter EBITDA for Mar 20 to be $-10.57M, with a high of $-8.45M and a low of $-12.68M. This is -158.94% lower than Enanta Pharmaceuticals's previous annual EBITDA (Dec 19) of $17.93M.
Enanta Pharmaceuticals Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 11 | 10 |
| Net Income | - | - | - | - | - | - | - | $-33.41M | $-28.11M | $-39.06M | $-37.66M | $-28.99M | $-26.35M | $-31.70M | $-33.34M | $-30.11M | $-24.60M | $-24.02M | $-22.05M | $-8.33M | $-29.34M | $-14.27M | $-6.00M | $13.44M | $9.19M | $7.04M | $4.14M | $12.55M | $-5.39M | $-1.65M |
| Avg Forecast | $-31.24M | $-30.76M | $-29.76M | $-26.85M | $-24.58M | $-30.34M | $-46.24M | $-25.97M | $-44.99M | $-47.62M | $-36.55M | $-22.87M | $-26.52M | $-29.43M | $-28.89M | $-23.35M | $-25.65M | $-27.87M | $-19.57M | $-16.24M | $-18.90M | $-17.90M | $-8.99M | $11.57M | $11.20M | $3.45M | $16.79M | $10.66M | $-6.81M | $-4.29M |
| High Forecast | $-29.50M | $-29.05M | $-29.55M | $-25.11M | $-23.22M | $-28.65M | $-36.99M | $-23.55M | $-25.87M | $-44.98M | $-29.24M | $-18.29M | $-26.52M | $-29.43M | $-23.12M | $-23.35M | $-25.65M | $-27.87M | $-15.66M | $-16.24M | $-18.90M | $-17.90M | $-7.19M | $11.57M | $11.20M | $3.45M | $20.14M | $12.79M | $-5.45M | $-3.43M |
| Low Forecast | $-32.97M | $-32.47M | $-29.96M | $-28.36M | $-25.95M | $-32.02M | $-55.48M | $-29.71M | $-52.87M | $-50.26M | $-43.86M | $-27.44M | $-26.52M | $-29.43M | $-34.67M | $-23.35M | $-25.65M | $-27.87M | $-23.48M | $-16.24M | $-18.90M | $-17.90M | $-10.78M | $11.57M | $11.20M | $3.45M | $13.43M | $8.53M | $-8.17M | $-5.15M |
| Surprise % | - | - | - | - | - | - | - | 1.29% | 0.62% | 0.82% | 1.03% | 1.27% | 0.99% | 1.08% | 1.15% | 1.29% | 0.96% | 0.86% | 1.13% | 0.51% | 1.55% | 0.80% | 0.67% | 1.16% | 0.82% | 2.04% | 0.25% | 1.18% | 0.79% | 0.38% |
Enanta Pharmaceuticals's average Quarter net income forecast for Mar 20 is $-8.99M, with a range of $-10.78M to $-7.19M. ENTA's average Quarter net income forecast represents a -166.85% decrease compared to the company's last Quarter net income of $13.44M (Dec 19).
Enanta Pharmaceuticals SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 11 | 10 |
| SG&A | - | - | - | - | - | - | - | $16.52M | $13.79M | $12.62M | $13.78M | $12.70M | $12.57M | $12.93M | $10.48M | $9.51M | $8.36M | $8.48M | $8.33M | $7.38M | $6.73M | $6.82M | $6.88M | $6.92M | $6.16M | $6.15M | $6.78M | $5.71M | $5.46M | $4.43M |
| Avg Forecast | $8.06M | $8.61M | $8.65M | $9.39M | $9.36M | $9.10M | $14.42M | $11.45M | $9.13M | $9.49M | $11.40M | $7.22M | $8.71M | $7.77M | $9.01M | $10.30M | $9.91M | $8.23M | $7.39M | $10.44M | $9.62M | $9.91M | $10.30M | $21.86M | $21.06M | $17.68M | $27.46M | $4.84M | $6.90M | $11.55M |
| High Forecast | $8.40M | $8.97M | $8.72M | $10.38M | $9.38M | $9.10M | $17.30M | $11.87M | $17.26M | $9.90M | $13.68M | $8.66M | $8.71M | $7.77M | $10.81M | $10.30M | $9.91M | $8.23M | $8.87M | $10.44M | $9.62M | $9.91M | $12.36M | $21.86M | $21.06M | $17.68M | $32.95M | $5.81M | $8.28M | $13.86M |
| Low Forecast | $7.71M | $8.24M | $8.57M | $8.40M | $9.34M | $9.10M | $11.54M | $11.03M | $4.09M | $9.09M | $9.12M | $5.78M | $8.71M | $7.77M | $7.21M | $10.30M | $9.91M | $8.23M | $5.91M | $10.44M | $9.62M | $9.91M | $8.24M | $21.86M | $21.06M | $17.68M | $21.97M | $3.88M | $5.52M | $9.24M |
| Surprise % | - | - | - | - | - | - | - | 1.44% | 1.51% | 1.33% | 1.21% | 1.76% | 1.44% | 1.66% | 1.16% | 0.92% | 0.84% | 1.03% | 1.13% | 0.71% | 0.70% | 0.69% | 0.67% | 0.32% | 0.29% | 0.35% | 0.25% | 1.18% | 0.79% | 0.38% |
Enanta Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $14.42M, based on 1 Wall Street analysts, with a range of $11.54M to $17.30M. The forecast indicates a -12.71% fall compared to ENTA last annual SG&A of $16.52M (Dec 23).
Enanta Pharmaceuticals EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 7 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 11 | 10 |
| EPS | - | - | - | - | - | - | - | $-1.58 | $-1.34 | $-1.86 | $-1.79 | $-1.39 | $-1.28 | $-1.53 | $-1.62 | $-1.48 | $-1.22 | $-1.19 | $-1.09 | $-0.41 | $-1.46 | $-0.71 | $-0.30 | $0.68 | $0.47 | $0.36 | $0.21 | $0.65 | $-0.28 | $-0.09 |
| Avg Forecast | $-1.48 | $-1.45 | $-1.41 | $-1.27 | $-1.16 | $-1.43 | $-1.34 | $-1.23 | $-2.12 | $-2.25 | $-1.96 | $-1.57 | $-1.25 | $-1.39 | $-1.42 | $-1.10 | $-1.21 | $-1.32 | $-0.98 | $-0.77 | $-0.89 | $-0.84 | $-0.75 | $0.55 | $0.53 | $0.16 | $-0.06 | $0.45 | $-0.48 | $0.26 |
| High Forecast | $-1.39 | $-1.37 | $-1.40 | $-1.19 | $-1.10 | $-1.35 | $-1.26 | $-1.11 | $-1.22 | $-2.12 | $-1.85 | $-1.49 | $-1.25 | $-1.39 | $-1.42 | $-1.10 | $-1.21 | $-1.32 | $-0.98 | $-0.77 | $-0.89 | $-0.84 | $-0.75 | $0.55 | $0.53 | $0.16 | $-0.06 | $0.54 | $-0.38 | $0.31 |
| Low Forecast | $-1.56 | $-1.53 | $-1.41 | $-1.34 | $-1.23 | $-1.51 | $-1.41 | $-1.40 | $-2.50 | $-2.37 | $-2.07 | $-1.66 | $-1.25 | $-1.39 | $-1.42 | $-1.10 | $-1.21 | $-1.32 | $-0.98 | $-0.77 | $-0.89 | $-0.84 | $-0.75 | $0.55 | $0.53 | $0.16 | $-0.06 | $0.36 | $-0.58 | $0.21 |
| Surprise % | - | - | - | - | - | - | - | 1.29% | 0.63% | 0.83% | 0.91% | 0.88% | 1.02% | 1.10% | 1.14% | 1.34% | 1.01% | 0.90% | 1.11% | 0.53% | 1.64% | 0.84% | 0.40% | 1.24% | 0.89% | 2.21% | -3.61% | 1.44% | 0.58% | -0.35% |
According to 4 Wall Street analysts, Enanta Pharmaceuticals's projected average Quarter EPS for Mar 20 is $-0.75, with a low estimate of $-0.75 and a high estimate of $-0.75. This represents a -210.50% decrease compared to ENTA previous annual EPS of $0.68 (Dec 19).
Enanta Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals | $6.13 | $65.67 | 971.29% | Buy |
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |